Search Results

The SURx Laparoscopic Probe (LP) Radio Frequency (RF) System is indicated for shrinkage and stabilization of female pelvic tissue for treatment of Type II stress urinary incontinence due to hypermobility in women not eligible for major corrective surgery.

The SURx LP System consists of two components: the SURx LP Generator and the SURx LP Applicator. The SURx LP Applicator connects to the Generator. The Applicator also provides irrigation to the treatment site. The SURx LP Applicator is supplied sterile and intended for single use. The Applicator uses a bipolar design, which means that a return pad is not required for operation. The tip of the Applicator contains a thermistor to monitor temperature at the targeted area. The SURx LP Generator is a radiofrequency (RF) electronic instrument. Software is utilized in the operation of the SURx LP Generator.

The provided text describes the regulatory clearance of a medical device and mentions clinical evaluations but does not contain the detailed information required to fill out the table of acceptance criteria or the specifics of a study proving a device meets those criteria.

Specifically, the document states:

• "Results of clinical evaluations were used to demonstrate that the SURx LP System functioned as clinically intended."
• "Sufficient data have been gathered from clinical studies to determine that the SURx LP System performs as clinically intended and that no new issues of safety and effectiveness are introduced."

However, it does not provide:

• A specific table of acceptance criteria (e.g., minimum accuracy, sensitivity, specificity thresholds).
• The reported device performance metrics against such criteria.
• The sample size for the test set or its provenance.
• Details about ground truth establishment (number/qualifications of experts, adjudication method, type of ground truth).
• Information on MRMC studies or standalone algorithm performance.
• Sample size for and ground truth establishment methods for a training set.

Therefore, based only on the provided text, I cannot complete the requested table or provide a detailed description of the study as requested. The document's purpose is to confirm regulatory clearance based on substantial equivalence, not to detail the full clinical study methodology and results.

Ask a specific question about this device

The Minnova Pelvic Floor Stimulation System is indicated for acute and ongoing treatment of urinary incontinence in cases where the following results may improve urinary control: Improvement of urethral sphincter closure, Strengthening of pelvic floor muscles, Inhibition of the detruser muscle through reflective mechanisms.

The Minnova Pelvic Floor Stimulation System is comprised of a external stimulator and an electrode. The device when used with the Innova® ComfortPulse® Vaginal electrodes (ComfortPulse Electrodes) (K964577 currently under review at the FDA), Innova Vaginal Electrode (K910081), and Innova® Rectal Stimulation Electrode (Innova Rectal Electrode) (K954272), stimulates the muscles of the pelvic floor to achieve and maintain urinary continence. The electrodes are identical to those previously submitted except for the addition of touchproof connectors to comply with "Medical Devices; Performance Standards for Electrode Lead Wires and Banning of Unprotected Electrode Lead Wires; Proposed Rule." There is no adapter required to connect the electrodes to the device. The components of the system are placed in a softsided carrying case.

This document does not contain information about acceptance criteria or a study that proves the device meets those criteria. It primarily describes the device's components, technical specifications, intended use, and the types of non-clinical tests performed to demonstrate substantial equivalence to predicate devices. There is no mention of clinical studies, sample sizes, expert involvement, ground truth, or MRMC studies.

Ask a specific question about this device